Clinical Trial Update: A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) [Phase 3]

View source ↗

Summary

Amgen completed a Phase 3 trial (ROCKET-VOYAGER) evaluating rocatinlimab’s impact on vaccine antibody response in patients with moderate-to-severe atopic dermat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 3 | Status: COMPLETED